Eagle Health Investments LP Makes New $5.36 Million Investment in COMPASS Pathways PLC Sponsored ADR $CMPS

Eagle Health Investments LP acquired a new stake in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 935,450 shares of the company’s stock, valued at approximately $5,360,000. COMPASS Pathways comprises approximately 1.4% of Eagle Health Investments LP’s investment portfolio, making the stock its 18th largest position. Eagle Health Investments LP owned 0.98% of COMPASS Pathways at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Nantahala Capital Management LLC grew its position in COMPASS Pathways by 47.7% during the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after buying an additional 1,350,698 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in COMPASS Pathways in the second quarter valued at approximately $3,011,000. Schroder Investment Management Group acquired a new stake in shares of COMPASS Pathways during the 2nd quarter valued at $1,525,000. Simplify Asset Management Inc. acquired a new position in shares of COMPASS Pathways in the third quarter valued at approximately $1,662,000. Finally, 22NW LP increased its position in COMPASS Pathways by 36.5% in the 2nd quarter. 22NW LP now owns 882,844 shares of the company’s stock valued at $2,472,000 after acquiring an additional 236,285 shares during the period. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways News Roundup

Here are the key news stories impacting COMPASS Pathways this week:

• Positive Sentiment: COMP360 met the primary endpoint in a late‑stage (Phase 3) study, driving optimism about regulatory and commercial prospects for the psilocybin therapy. This is the main catalyst for the rally. Compass Pathways’ depression treatment meets main goal in late‑stage study
• Positive Sentiment: Compass announced it will report new clinical data from two ongoing Phase 3 trials (COMP005 and COMP006) and provided a timeline for additional Phase 3 results, reinforcing near‑term news flow that supports further upside. Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
• Positive Sentiment: Market activity shows heightened bullish positioning: unusually large call option volume (over 10,000 calls) and extremely heavy equity volume suggest speculative and institutional buying around the trial news, which amplified the stock move. (Internal trading/activity reports)
• Neutral Sentiment: Public and media coverage (Investing.com, PharmaLetter, MSN) amplified investor attention; press coverage supports momentum but doesn’t guarantee regulatory approval or commercial success. Compass Pathways stock soars after positive Phase 3 trial results
• Neutral Sentiment: Reported short‑interest data in the filings appears erroneous (0 shares / NaN changes) and is unreliable as an indicator of bearish positioning or squeeze potential at present.
• Neutral Sentiment: Third‑party analyst commentary and forecasts (e.g., Lifesci Capital coverage) exist but are secondary to the actual trial readouts for near‑term price action. What is Lifesci Capital’s Forecast for CMPS FY2025 Earnings?
• Negative Sentiment: Compass launched a proposed $150M public offering of ADSs (and pre‑funded warrants), which can dilute existing shareholders and may cap near‑term upside despite the positive data. Investors should weigh dilution risk against trial progress. Compass Pathways Launches Proposed $150.0 Million Public Offering

Analyst Ratings Changes

CMPS has been the topic of several recent analyst reports. Lifesci Capital upgraded shares of COMPASS Pathways to a “strong-buy” rating in a report on Thursday, February 12th. Compass Point set a $15.00 price target on COMPASS Pathways in a report on Thursday, February 12th. Morgan Stanley lifted their price objective on shares of COMPASS Pathways from $10.00 to $11.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Royal Bank Of Canada boosted their target price on shares of COMPASS Pathways from $16.00 to $21.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of COMPASS Pathways in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.11.

COMPASS Pathways Stock Up 31.3%

CMPS opened at $7.63 on Wednesday. The firm has a market capitalization of $732.63 million, a P/E ratio of -2.81 and a beta of 1.92. COMPASS Pathways PLC Sponsored ADR has a one year low of $2.25 and a one year high of $8.80. The company has a fifty day moving average price of $6.77 and a 200-day moving average price of $5.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23.

COMPASS Pathways Company Profile

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.